NASDAQ$SLDB

Solid Biosciences Inc · Q3 2021 earnings

Q3 2021 earnings · · Investor relations

Headline financials

Total Revenue

$3.54M

Previous: $0.00
EPS (adj)

-$2.40

Previous: -$6.60+63.6%
Capital Expenditures

$237K

Previous: -$839K+128.2%
Free Cash Flow

-$18.7M

Previous: -$22.1M+15.5%
Net Income

-$18M

Previous: -$21.2M+15.4%
Operating Income

-$18M

Previous: -$21.2M+15.1%
Cash & Equivalents

$110M

Previous: $24.8M+342.3%
Total Assets

$249M

Previous: $40.5M+514.5%
Stock-Based Comp

$3.42M

No prior period

Revenue & EPS history

Solid Biosciences · Revenue · Quarterly

$3.54M

Q3 2021
Beat estimate in 4 of 8 quarters(50%)
ActualEstimate

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q3 2021

Historical avgQ3 2021

-3.2%

Avg return

Earnings day

+0.7%

Avg return

5 days after

+3.1%

Avg return

30 days after

50%

16 / 32 earnings

Positive

+19.0%

Q2 2019

Best reaction

-72.2%

Q3 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026+2.0%+14.2%+14.7%
Q3 2025+7.4%+15.3%+46.8%
Q1 2025+8.3%+14.2%+71.2%
Q4 2024+5.3%-9.6%-50.5%
Q3 2024-2.9%+0.8%-15.0%
Q2 2024+16.6%+23.9%+7.8%
Q1 2024-6.6%-8.4%-20.7%
Q4 2023+7.7%+17.2%-9.0%
Q3 2023-23.9%-22.9%+80.7%
Q2 2023-1.1%-1.1%-12.9%
Q1 2023+1.9%+1.0%+2.3%
Q4 2022-2.6%+5.0%+28.6%
Q3 2022+3.9%+4.6%-0.8%
Q2 2022+6.5%+15.3%-10.8%
Q1 2022-24.2%-29.0%-23.9%
Q4 2021-7.0%+34.0%-0.9%
Q3 2021+13.9%+3.7%-21.8%
Q2 2021-3.0%-7.1%-1.1%
Q1 2021-20.0%-15.8%-7.4%
Q4 2020-32.5%-38.9%-44.3%
Q3 2020-0.6%-1.9%+12.0%
Q2 2020+0.0%+8.0%-13.6%
Q1 2020-12.2%-7.3%+2.1%
Q4 2019+18.5%-4.5%-22.0%
Q3 2019-72.2%-68.1%-61.3%
Q2 2019+19.0%+79.9%+96.1%
Q1 2019-31.2%-34.2%-43.2%
Q4 2018+0.3%+4.7%-9.9%
Q3 2018+13.8%+3.8%-2.6%
Q2 2018-1.2%-1.1%+2.5%
Q1 2018+11.6%+15.2%+19.6%
Q4 2017+1.9%+12.7%+86.2%
Q3 2017
Q4 2016
Q1 2016

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro